GET
json api

Project List

List projects.

Fields

id (integer)

Primary key.

Expansions

To activate relation expansion add the desired fields as a comma separated list to the expand query parameter like this:

?expand=<field>,<field>,<field>,...

The following relational fields can be expanded:

  • organization
  • category
  • type
  • partner_function
  • manager
  • contact
  • status
  • grant
  • research
  • event
  • study
  • language
  • program
  • funders

Filters

To filter for exact value matches:

?<fieldname>=<value>

Possible exact filters:

  • organization
  • category
  • manager
  • contact
  • status
  • grant
  • research
  • study
  • language
  • funders
  • program

For advanced filtering use lookups:

?<fieldname>__<lookup>=<value>

All fields with advanced lookups can also be used for exact value matches as described above.

Possible advanced lookups:

  • begin_planned: gt, gte, lt, lte
  • begin_effective: gt, gte, lt, lte
  • end_planned: gt, gte, lt, lte
  • end_effective: gt, gte, lt, lte
GET /v1/research/project/?format=api&offset=280&ordering=begin_effective
HTTP 200 OK
  Allow: GET, HEAD, OPTIONS
  Content-Type: application/json
  Vary: Accept
  
  {
    "count": 2244,
    "next": "https://api-test.medunigraz.at/v1/research/project/?format=api&limit=20&offset=300&ordering=begin_effective",
    "previous": "https://api-test.medunigraz.at/v1/research/project/?format=api&limit=20&offset=260&ordering=begin_effective",
    "results": [
        {
            "id": 1578,
            "title": {
                "de": "Whole Genome Screening des Menschen bei der Menigokokkensepsis",
                "en": "Whole Genome Screening des Menschen bei der Menigokokkensepsis"
            },
            "short": "Meningokokkensepsis",
            "url": null,
            "abstract": {
                "de": "Meningokokkenerkrankungen betreffen fast immer vorher vollkommen gesunde Kinder und können innerhalb weniger Stunden zum Tod führen. Die Erkrankung ist selten, in Österreich werden jährlich zwischen 80 und 100 Fälle beobachtet. Betroffen sind fast ausschließlich Kinder. Die septische Verlaufsform ist durch die rasche Entwicklung eines schweren Schocks mit verminderter Durchblutung der Haut, Bewusstlosigkeit, Multiorganversagen und schwerer Stö-rung der Blutgerinnung charakterisiert, die Sterblichkeit liegt trotz intensivmedizinischer Bemü-hungen noch immer bei etwa 25%.\r\nEs sind nun Genomanalysen verfügbar, mit denen das gesamte menschliche Genom (3 Mrd. Basenpaare) untersucht werden kann. Mit diesen neuen Methoden können alle genetischen Än-derungen, die für das Auftreten und den Verlauf einer Erkrankung verantwortlich sind, unter-sucht werden. In den letzten 2 Jahren sind bereits mehrere solche whole genome association studies (GWAs) veröffentlicht worden, jedoch wurden noch keine Ergebnisse zur Genetik der Sepsis gezeigt.\r\nMit Hilfe unseres Netzwerkes wäre es uns möglich, mit zwei weiteren Forschungsgruppen eine Kooperation zur Klärung der genetischen Ursachen der Meningokokkensepsis zu etablieren. Das so gebildete Kollektiv würde das weltweit größte Netzwerk zur Untersuchung von Meningo-kokkenerkrankungen darstellen. Es würde über 3000 europäischen Patienten sowie 700 Kon-trollproben umfassen und sich aus einer britischen, niederländischen, sowie unserer mitteleuro-päischen Kohorte zusammensetzen.\r\nIn Summe würden sich bei dem von uns primär eingesetzten Probenkollektiv von 200-400 Pati-enten  220 – 440 Millionen Einzeluntersuchungen zur Darstellung des gesamten Genoms jeder einzelnen Patienten- bzw. Kontrollprobe ergeben.\r\nDas Ziel dieser weltweiten Kooperation ist es, die genetischen Variablen, welche zu einer Me-ningokokkensepsis führen, aufzudecken. Es soll so eine erste komplette Übersicht über die Ge-netik der Sepsiserkrankung erreicht werden. Die Aufklärung der involvierten Gene kann als An-gelpunkt für die weiterführende Forschung gesehen werden und bildet eine erste Grundlage für die Entwicklung selektiver (Kombinations-) Therapien.",
                "en": "Meningokokkenerkrankungen betreffen fast immer vorher vollkommen gesunde Kinder und können innerhalb weniger Stunden zum Tod führen. Die Erkrankung ist selten, in Österreich werden jährlich zwischen 80 und 100 Fälle beobachtet. Betroffen sind fast ausschließlich Kinder. Die septische Verlaufsform ist durch die rasche Entwicklung eines schweren Schocks mit verminderter Durchblutung der Haut, Bewusstlosigkeit, Multiorganversagen und schwerer Stö-rung der Blutgerinnung charakterisiert, die Sterblichkeit liegt trotz intensivmedizinischer Bemü-hungen noch immer bei etwa 25%.\r\nEs sind nun Genomanalysen verfügbar, mit denen das gesamte menschliche Genom (3 Mrd. Basenpaare) untersucht werden kann. Mit diesen neuen Methoden können alle genetischen Än-derungen, die für das Auftreten und den Verlauf einer Erkrankung verantwortlich sind, unter-sucht werden. In den letzten 2 Jahren sind bereits mehrere solche whole genome association studies (GWAs) veröffentlicht worden, jedoch wurden noch keine Ergebnisse zur Genetik der Sepsis gezeigt.\r\nMit Hilfe unseres Netzwerkes wäre es uns möglich, mit zwei weiteren Forschungsgruppen eine Kooperation zur Klärung der genetischen Ursachen der Meningokokkensepsis zu etablieren. Das so gebildete Kollektiv würde das weltweit größte Netzwerk zur Untersuchung von Meningo-kokkenerkrankungen darstellen. Es würde über 3000 europäischen Patienten sowie 700 Kon-trollproben umfassen und sich aus einer britischen, niederländischen, sowie unserer mitteleuro-päischen Kohorte zusammensetzen.\r\nIn Summe würden sich bei dem von uns primär eingesetzten Probenkollektiv von 200-400 Pati-enten  220 – 440 Millionen Einzeluntersuchungen zur Darstellung des gesamten Genoms jeder einzelnen Patienten- bzw. Kontrollprobe ergeben.\r\nDas Ziel dieser weltweiten Kooperation ist es, die genetischen Variablen, welche zu einer Me-ningokokkensepsis führen, aufzudecken. Es soll so eine erste komplette Übersicht über die Ge-netik der Sepsiserkrankung erreicht werden. Die Aufklärung der involvierten Gene kann als An-gelpunkt für die weiterführende Forschung gesehen werden und bildet eine erste Grundlage für die Entwicklung selektiver (Kombinations-) Therapien."
            },
            "begin_planned": "2009-01-01T01:00:00+01:00",
            "begin_effective": "2008-07-17T02:00:00+02:00",
            "end_planned": "2009-10-31T01:00:00+01:00",
            "end_effective": "2010-05-31T02:00:00+02:00",
            "assignment": "2008-07-16T13:03:29+02:00",
            "program": null,
            "subprogram": null,
            "organization": 14091,
            "category": 10,
            "type": 10,
            "partner_function": 4,
            "manager": 51647,
            "contact": 54004,
            "status": 2,
            "research": 1,
            "grant": 10,
            "event": null,
            "study": null,
            "language": null,
            "funders": [
                135
            ],
            "funder_projectcode": null,
            "ethics_committee": null,
            "edudract_number": null,
            "persons": [
                "1578-51647-10"
            ]
        },
        {
            "id": 1645,
            "title": {
                "de": "Influence of Antioxidative Agents like Resveratrol, Quercetin-dihydrate, and Seleno-L-Methionine on Human Synoviocytes of Osteoarthritis (OA), Rheumatoid Arthritis (RA) and Psoriasis Arthritis (PsA) Patients",
                "en": "Influence of Antioxidative Agents like Resveratrol, Quercetin-dihydrate, and Seleno-L-Methionine on Human Synoviocytes of Osteoarthritis (OA), Rheumatoid Arthritis (RA) and Psoriasis Arthritis (PsA) Patients"
            },
            "short": "Influence of Antioxidative Agents",
            "url": null,
            "abstract": {
                "de": "Osteoarthritis is the most prevalent disorder of the musculoskeletal system and has a very high socioeconomic impact. Current treatments for Osteoarthritis are only symptomatic, because they do not act on the causes of Arthritis and do not stop the progression of the disease. This study is designed to investigate the effect of Resveratrol, Quercetin, and Selenium on healthy human synovial cells compared to synovial cells from OA and RA patients. We propose that these chemo preventive agents cause a growth rate decrease in synovial tissue and furthermore an inhibition of proinflammatory factors as well as an increase in factors favouring apoptosis and cell death. \r\nEspecially Resveratrol is known as a potent specific inhibitor of inflammation, but its potency has not been tested on human synovial cells. If the potency in decreasing inflammatory Interleukins is similar to the results of animal experiments, it would be an enormous effort for treatment of Osteoarthritis and Rheumatoid Arthritis. This study should be undertaken to define a possible systemic or local application of Resveratrol compared to Quercetin and Selenium. A close interaction between clinicians and basic scientists is necessary because of the combination of analytical, functional and molecular methods.\r\n",
                "en": "Osteoarthritis is the most prevalent disorder of the musculoskeletal system and has a very high socioeconomic impact. Current treatments for Osteoarthritis are only symptomatic, because they do not act on the causes of Arthritis and do not stop the progression of the disease. This study is designed to investigate the effect of Resveratrol, Quercetin, and Selenium on healthy human synovial cells compared to synovial cells from OA and RA patients. We propose that these chemo preventive agents cause a growth rate decrease in synovial tissue and furthermore an inhibition of proinflammatory factors as well as an increase in factors favouring apoptosis and cell death. \r\nEspecially Resveratrol is known as a potent specific inhibitor of inflammation, but its potency has not been tested on human synovial cells. If the potency in decreasing inflammatory Interleukins is similar to the results of animal experiments, it would be an enormous effort for treatment of Osteoarthritis and Rheumatoid Arthritis. This study should be undertaken to define a possible systemic or local application of Resveratrol compared to Quercetin and Selenium. A close interaction between clinicians and basic scientists is necessary because of the combination of analytical, functional and molecular methods.\r\n"
            },
            "begin_planned": "2008-09-01T02:00:00+02:00",
            "begin_effective": "2008-08-01T02:00:00+02:00",
            "end_planned": "2009-08-31T02:00:00+02:00",
            "end_effective": "2010-08-31T02:00:00+02:00",
            "assignment": "2008-10-29T16:01:05+01:00",
            "program": 79,
            "subprogram": null,
            "organization": 14052,
            "category": 10,
            "type": 10,
            "partner_function": 4,
            "manager": null,
            "contact": null,
            "status": 2,
            "research": 1,
            "grant": 10,
            "event": null,
            "study": null,
            "language": null,
            "funders": [
                12
            ],
            "funder_projectcode": null,
            "ethics_committee": null,
            "edudract_number": null,
            "persons": [
                "1645-50696-12",
                "1645-57343-12"
            ]
        },
        {
            "id": 1804,
            "title": {
                "de": "European network of paediatric Hodgkin´s lymphoma- European-wide organisation of quality controlled treatment (Paediaric Hodgkin network)",
                "en": "European network of paediatric Hodgkin´s lymphoma- European-wide organisation of quality controlled treatment (Paediaric Hodgkin network)"
            },
            "short": "Paediaric Hodgkin network",
            "url": null,
            "abstract": {
                "de": "Build on the experience from national trials for paediatric Hodgkin's lymphoma (PHL) experts from 12 EU countries decided on a common protocol to individualise PHL treatment.\r\n\r\nThe general objective of this proposal is to ensure a high-quality teatment for all affected patients from paediatric Hodgkin's lymphoma independent of their social or geographical origin by establishing a shared case management and expert system using a medical image and communication network. Aim of the high-quality treatment planning algorithm is to achieve high rates for event-free survival with the least necessary treatment toxicity in every child.",
                "en": "Build on the experience from national trials for paediatric Hodgkin's lymphoma (PHL) experts from 12 EU countries decided on a common protocol to individualise PHL treatment.\r\n\r\nThe general objective of this proposal is to ensure a high-quality teatment for all affected patients from paediatric Hodgkin's lymphoma independent of their social or geographical origin by establishing a shared case management and expert system using a medical image and communication network. Aim of the high-quality treatment planning algorithm is to achieve high rates for event-free survival with the least necessary treatment toxicity in every child."
            },
            "begin_planned": null,
            "begin_effective": "2008-08-01T02:00:00+02:00",
            "end_planned": null,
            "end_effective": "2011-07-31T02:00:00+02:00",
            "assignment": "2009-04-30T19:27:24+02:00",
            "program": 21,
            "subprogram": null,
            "organization": 14107,
            "category": 10,
            "type": 10,
            "partner_function": 2,
            "manager": 51727,
            "contact": 51727,
            "status": 2,
            "research": 2,
            "grant": 10,
            "event": null,
            "study": null,
            "language": null,
            "funders": [
                10
            ],
            "funder_projectcode": null,
            "ethics_committee": null,
            "edudract_number": null,
            "persons": [
                "1804-51727-10"
            ]
        },
        {
            "id": 1582,
            "title": {
                "de": "Bioengineering and clinical assessment of high-tech acupuncture - a Sino-Austrian research pilot study",
                "en": "Bioengineering and clinical assessment of high-tech acupuncture - a Sino-Austrian research pilot study"
            },
            "short": "TCM_Bioengineering",
            "url": null,
            "abstract": {
                "de": "High-Tech Akupunktur, also die Entmystifizierung der Akupunktur mit modernsten technischen Methoden, stellt eine wichtige Brückenfunktion in den geplanten Sino-Austrian Research Projektvorhaben dar.\r\n\r\nHauptziel des gegenständlichen Pilotprojektes ist es, erstmals Grundlagenforschung auf dem Gebiet der High-Tech Akupunktur, welche seit 10 Jahren in Graz erfolgreich durchgeführt wird, mit notwendigen klinischen Pilotstudien in China zu verbinden. Diese klinischen Studien (Untersuchungen z.B. an Schmerzpatienten) sollen in China von der China Academy of Chinese Medical Sciences (CACMS) in Peking organisiert und mit zum Teil in Österreich entwickeltem und wissenschaftlich erstmals erprobten Equipment und Know-how berwerkstelligt werden.",
                "en": "High-Tech Akupunktur, also die Entmystifizierung der Akupunktur mit modernsten technischen Methoden, stellt eine wichtige Brückenfunktion in den geplanten Sino-Austrian Research Projektvorhaben dar.\r\n\r\nHauptziel des gegenständlichen Pilotprojektes ist es, erstmals Grundlagenforschung auf dem Gebiet der High-Tech Akupunktur, welche seit 10 Jahren in Graz erfolgreich durchgeführt wird, mit notwendigen klinischen Pilotstudien in China zu verbinden. Diese klinischen Studien (Untersuchungen z.B. an Schmerzpatienten) sollen in China von der China Academy of Chinese Medical Sciences (CACMS) in Peking organisiert und mit zum Teil in Österreich entwickeltem und wissenschaftlich erstmals erprobten Equipment und Know-how berwerkstelligt werden."
            },
            "begin_planned": "2007-09-17T02:00:00+02:00",
            "begin_effective": "2008-09-01T02:00:00+02:00",
            "end_planned": "2008-09-16T02:00:00+02:00",
            "end_effective": "2011-08-31T02:00:00+02:00",
            "assignment": "2008-07-17T12:51:26+02:00",
            "program": null,
            "subprogram": null,
            "organization": 14044,
            "category": 10,
            "type": 10,
            "partner_function": 2,
            "manager": null,
            "contact": null,
            "status": 2,
            "research": 1,
            "grant": 10,
            "event": null,
            "study": null,
            "language": null,
            "funders": [
                25,
                472
            ],
            "funder_projectcode": null,
            "ethics_committee": null,
            "edudract_number": null,
            "persons": []
        },
        {
            "id": 1510,
            "title": {
                "de": "EuroSTEC: Soft tissue engineering for congenital birth defects in children: from \"biomatrix - cell interaction - model system\" to clinical trials",
                "en": "EuroSTEC: Soft tissue engineering for congenital birth defects in children: from \"biomatrix - cell interaction - model system\" to clinical trials"
            },
            "short": "IMPPACT",
            "url": null,
            "abstract": {
                "de": "IMPPACT will develop an intervention planning and monitoring application for Radiofrequency Ablation (RFA) of malignant liver tumours. RFA is a minimally invasive form to treat cancer without open surgery, by placing a needle inside the malignancy and destroying it through intensive heating. Though the advantages of this approach ale obvious, the intervention is currently hard to plan, almost impossible to monitor or assess, and therefore is not the first choice for treatment. IMPPACT will develop a physiological model of the liver and simulate the intervention's result, accounting for patient specific physiological factors. Gaps in the understanding of particular aspects of the RFA treatment will be closed by multi-scale studies on cells and animals. New findings will be evaluated microscopically and transformed into macroscopic equations. The long-established bio-heat equation will be extended to incorporate multiple scales. Validation will be performed at multiple levels. Images from ongoing patient treatment will be used to cross check validity for human physiology. Final validation will be performed at macroscopic level through visual comparison of simulation and treatment results gathered in animal studies and during patient treatment. This extensive validation together with a user-centered software design approach will guarantee suitability of the solution for clinical practice. The consortium consists of two Hospitals, three Universities, one Research Institute and one industrial SME. The final project deliverables will be the patient specific intervention planning system and an augmented reality training simulator for the RFA intervention.",
                "en": "IMPPACT will develop an intervention planning and monitoring application for Radiofrequency Ablation (RFA) of malignant liver tumours. RFA is a minimally invasive form to treat cancer without open surgery, by placing a needle inside the malignancy and destroying it through intensive heating. Though the advantages of this approach ale obvious, the intervention is currently hard to plan, almost impossible to monitor or assess, and therefore is not the first choice for treatment. IMPPACT will develop a physiological model of the liver and simulate the intervention's result, accounting for patient specific physiological factors. Gaps in the understanding of particular aspects of the RFA treatment will be closed by multi-scale studies on cells and animals. New findings will be evaluated microscopically and transformed into macroscopic equations. The long-established bio-heat equation will be extended to incorporate multiple scales. Validation will be performed at multiple levels. Images from ongoing patient treatment will be used to cross check validity for human physiology. Final validation will be performed at macroscopic level through visual comparison of simulation and treatment results gathered in animal studies and during patient treatment. This extensive validation together with a user-centered software design approach will guarantee suitability of the solution for clinical practice. The consortium consists of two Hospitals, three Universities, one Research Institute and one industrial SME. The final project deliverables will be the patient specific intervention planning system and an augmented reality training simulator for the RFA intervention."
            },
            "begin_planned": "2008-06-01T02:00:00+02:00",
            "begin_effective": "2008-09-01T02:00:00+02:00",
            "end_planned": "2011-05-31T02:00:00+02:00",
            "end_effective": "2011-12-31T01:00:00+01:00",
            "assignment": "2008-04-09T17:00:52+02:00",
            "program": 24,
            "subprogram": null,
            "organization": 14073,
            "category": 10,
            "type": 10,
            "partner_function": 2,
            "manager": 50874,
            "contact": 50874,
            "status": 2,
            "research": 3,
            "grant": 10,
            "event": null,
            "study": null,
            "language": null,
            "funders": [
                10
            ],
            "funder_projectcode": null,
            "ethics_committee": null,
            "edudract_number": null,
            "persons": [
                "1510-50874-10",
                "1510-62118-12",
                "1510-51955-12",
                "1510-51983-12"
            ]
        },
        {
            "id": 1586,
            "title": {
                "de": "Predictive markers of spontaneous preterm delivery",
                "en": "Predictive markers of spontaneous preterm delivery"
            },
            "short": "PREDICTIVE_MARKERS",
            "url": null,
            "abstract": {
                "de": "Frühgeburtlichkeit ist eine Hauptursache für perinatale Morbidität und Mortalität. In Bezug auf die neurologische Langzeitprognose ist die periventrikuläre Leukoenzephalomalazie (PVL) und die daraus resultierende Zerebralparese eine der häufigsten Ursachen für Behinderungen. Das Problem des Screenings und der Diagnostik liegt darin, dass die Frühgeburt ein Endpunkt verschiedener Ätiologien ist. In diesem Projekt wollen wir Marker evaluieren, die unterschiedlichen ätiologischen Kategorien entsprechen: Polymorphismen von Interleukin-10 und Interleukin-4 (Entzündung), SERPINE1 (uteroplazentare Vaskulopathie), messenger RNA von Cortikotropin-releasing-Hormon (Wehenauslösung) und Pentraxin 3 (Entzündung). Das Screeningpotential dieses Marker-Sets wird dabei sowohl für die Frühgeburt als auch für Frühgeburt mit Entwicklung einer PVL evaluiert. Diese Marker sollen den Einsatz prophylaktischer und therapeutischer Interventionen (Progesteron, anti-inflammatorische Interleukine) ermöglichen.",
                "en": "Frühgeburtlichkeit ist eine Hauptursache für perinatale Morbidität und Mortalität. In Bezug auf die neurologische Langzeitprognose ist die periventrikuläre Leukoenzephalomalazie (PVL) und die daraus resultierende Zerebralparese eine der häufigsten Ursachen für Behinderungen. Das Problem des Screenings und der Diagnostik liegt darin, dass die Frühgeburt ein Endpunkt verschiedener Ätiologien ist. In diesem Projekt wollen wir Marker evaluieren, die unterschiedlichen ätiologischen Kategorien entsprechen: Polymorphismen von Interleukin-10 und Interleukin-4 (Entzündung), SERPINE1 (uteroplazentare Vaskulopathie), messenger RNA von Cortikotropin-releasing-Hormon (Wehenauslösung) und Pentraxin 3 (Entzündung). Das Screeningpotential dieses Marker-Sets wird dabei sowohl für die Frühgeburt als auch für Frühgeburt mit Entwicklung einer PVL evaluiert. Diese Marker sollen den Einsatz prophylaktischer und therapeutischer Interventionen (Progesteron, anti-inflammatorische Interleukine) ermöglichen."
            },
            "begin_planned": "2008-09-01T02:00:00+02:00",
            "begin_effective": "2008-09-01T02:00:00+02:00",
            "end_planned": "2010-08-31T02:00:00+02:00",
            "end_effective": "2011-02-28T01:00:00+01:00",
            "assignment": "2008-07-25T13:12:34+02:00",
            "program": 79,
            "subprogram": null,
            "organization": 14064,
            "category": 10,
            "type": 10,
            "partner_function": 4,
            "manager": null,
            "contact": null,
            "status": 2,
            "research": 2,
            "grant": 10,
            "event": null,
            "study": null,
            "language": null,
            "funders": [
                12
            ],
            "funder_projectcode": null,
            "ethics_committee": null,
            "edudract_number": null,
            "persons": []
        },
        {
            "id": 1748,
            "title": {
                "de": "Anbahnungsfinanzierung Healthcare integrated Biobanking RP7 Health 1. Stufe",
                "en": "Anbahnungsfinanzierung Healthcare integrated Biobanking RP7 Health 1. Stufe"
            },
            "short": "HEALTHCARE_INTEGR_BIOBANKING",
            "url": null,
            "abstract": {
                "de": null,
                "en": null
            },
            "begin_planned": "2008-09-03T02:00:00+02:00",
            "begin_effective": "2008-09-03T02:00:00+02:00",
            "end_planned": "2008-12-31T01:00:00+01:00",
            "end_effective": "2008-12-31T01:00:00+01:00",
            "assignment": "2009-02-17T13:36:04+01:00",
            "program": 54,
            "subprogram": null,
            "organization": 14020,
            "category": 10,
            "type": 10,
            "partner_function": 4,
            "manager": 51663,
            "contact": 51663,
            "status": 2,
            "research": 5,
            "grant": 10,
            "event": null,
            "study": null,
            "language": null,
            "funders": [
                416
            ],
            "funder_projectcode": "821139",
            "ethics_committee": null,
            "edudract_number": null,
            "persons": [
                "1748-51663-10"
            ]
        },
        {
            "id": 1581,
            "title": {
                "de": "Identification and functional characterisation of Nuclear Orphan Receptors as Tumor Suppressor Genes in aggressive non-Hodgkin`s Lymphomas and acute lymphoblastic leukemia",
                "en": "Identification and functional characterisation of Nuclear Orphan Receptors as Tumor Suppressor Genes in aggressive non-Hodgkin`s Lymphomas and acute lymphoblastic leukemia"
            },
            "short": "non-Hodgkin`s Lymphoma",
            "url": null,
            "abstract": {
                "de": "NR4A1 (also called Nur77, TR3, or NGFI-B), NR4A2 (Nurr1 or RNR-1) and NR4A3 (Nor-1 or Minor) are three members of an orphan nuclear hormone receptor family referred to as Nur77 family. They are all transcription factors belonging to the superfamily of steroid nuclear hormone receptors. These nuclear hormone receptors (NR) are classified as early response genes, are induced by a diverse range of signals, including fatty acids, stress, growth factors, cytokines, peptide hormones, neurotransmitters, and physical stimuli for example magnetic fields or shear stress. In line with the pleiotropic physiological stimuli that induce the NR4A subgroup, these orphan NRs have been implicated in cell cycle regulation, apoptosis, inflammation, atherogenesis and more recently in carcinogenesis. \r\nThe ultimate growth of a tumour depends on not only the rate of tumour cell proliferation, but also the rate of tumour cell death (=apoptosis). NR4A1 controls both survival and death of cancer cells. \r\nIn contrast to NR4A1, only pro-survival effects, but not pro-apoptotic effects, have been reported for NR4A2. \r\nNR4A3 has been shown to be functionally redundant with NR4A1 in T-cell apoptosis. Results also suggest that NR4A1 and NR4A3 have non-redundant functions as well.\r\nThe most convincing evidence that nuclear orphan receptors function as critical tumor suppressors is the observation that the abrogation of nuclear receptors Nr4a3 and Nr4a1 leads to rapid development of acute myeloid leukemia. Evidence of nuclear orphan receptors acting as tumor suppressor genes in B-cell malignancies comes from the observation that Epstein-Barr virus EBNA 2 blocks NR4A1 mediated apoptosis in B-cells and from gene expression profiling in diffuse large B-cell lymphoma (DLBCL) in which over expression of NR4A3 is found in cured or refractory DLBCL, as opposed to a fatal course of disease. Hence, it is speculated that NR4A3 increases the apoptotic response to chemotherapy in curable DLBCL.\r\n\r\nThe aim of our study was to comprehensively study NR expression and function in B-cell malignancies and to define the nuclear orphan receptors NR4A1 and NR4A1 as cooperative putative tumor suppressor genes (TSG) in B-cell malignancies.\r\n\r\n",
                "en": "NR4A1 (also called Nur77, TR3, or NGFI-B), NR4A2 (Nurr1 or RNR-1) and NR4A3 (Nor-1 or Minor) are three members of an orphan nuclear hormone receptor family referred to as Nur77 family. They are all transcription factors belonging to the superfamily of steroid nuclear hormone receptors. These nuclear hormone receptors (NR) are classified as early response genes, are induced by a diverse range of signals, including fatty acids, stress, growth factors, cytokines, peptide hormones, neurotransmitters, and physical stimuli for example magnetic fields or shear stress. In line with the pleiotropic physiological stimuli that induce the NR4A subgroup, these orphan NRs have been implicated in cell cycle regulation, apoptosis, inflammation, atherogenesis and more recently in carcinogenesis. \r\nThe ultimate growth of a tumour depends on not only the rate of tumour cell proliferation, but also the rate of tumour cell death (=apoptosis). NR4A1 controls both survival and death of cancer cells. \r\nIn contrast to NR4A1, only pro-survival effects, but not pro-apoptotic effects, have been reported for NR4A2. \r\nNR4A3 has been shown to be functionally redundant with NR4A1 in T-cell apoptosis. Results also suggest that NR4A1 and NR4A3 have non-redundant functions as well.\r\nThe most convincing evidence that nuclear orphan receptors function as critical tumor suppressors is the observation that the abrogation of nuclear receptors Nr4a3 and Nr4a1 leads to rapid development of acute myeloid leukemia. Evidence of nuclear orphan receptors acting as tumor suppressor genes in B-cell malignancies comes from the observation that Epstein-Barr virus EBNA 2 blocks NR4A1 mediated apoptosis in B-cells and from gene expression profiling in diffuse large B-cell lymphoma (DLBCL) in which over expression of NR4A3 is found in cured or refractory DLBCL, as opposed to a fatal course of disease. Hence, it is speculated that NR4A3 increases the apoptotic response to chemotherapy in curable DLBCL.\r\n\r\nThe aim of our study was to comprehensively study NR expression and function in B-cell malignancies and to define the nuclear orphan receptors NR4A1 and NR4A1 as cooperative putative tumor suppressor genes (TSG) in B-cell malignancies."
            },
            "begin_planned": "2008-10-01T02:00:00+02:00",
            "begin_effective": "2008-10-01T02:00:00+02:00",
            "end_planned": "2010-09-30T02:00:00+02:00",
            "end_effective": "2010-09-30T02:00:00+02:00",
            "assignment": "2008-07-17T12:24:53+02:00",
            "program": null,
            "subprogram": null,
            "organization": 14082,
            "category": 10,
            "type": 10,
            "partner_function": 4,
            "manager": 51930,
            "contact": 51930,
            "status": 2,
            "research": 1,
            "grant": 10,
            "event": null,
            "study": null,
            "language": null,
            "funders": [
                836
            ],
            "funder_projectcode": null,
            "ethics_committee": null,
            "edudract_number": null,
            "persons": [
                "1581-51930-10"
            ]
        },
        {
            "id": 1577,
            "title": {
                "de": "Identification of specific endothelial binding-sites for inflammatory carbamylated low-density lipoproteins",
                "en": "Identification of specific endothelial binding-sites for inflammatory carbamylated low-density lipoproteins"
            },
            "short": "CARBAMYL_LDL_FWF08",
            "url": null,
            "abstract": {
                "de": "In renal disease, elevated levels of urea lead to an increased concentration of cyanate that reacts irreversible with amino groups of proteins through carbamylation reactions. High concentrations of carbamylated low-density-lipoproteins (cLDL) have recently been reported to accumulate in plasma of pateints with chronic renal failure, indicating that cLDL is by far the most abundant modified LDL found in human plasa. Of importance, carbamylated proteins may also be formed directly at sites of inflammation - even in the absence of renal disease- via the phagocyte derived inflammatory mediator myeloperoxidase (MPO). Active MPO is present in human atherosclerotic lesion material and has been shown to bind to low- and high-density lipoproteins. Thus, it can be assumed that MPO derived cyanate contributes to lipoprotein carbamylation at sites of inflammation. Recent clinical studies demonstrated that carbamylated proteins predict increased risk of coronary artery disease, future myocardial infarction, stroke and death.\r\n\r\nNo endothelial receptors of binding proteins that might trigger the potent pro-atherosclerotic effects of carbamylated LDL have yet been identified. Therefore, the aim of the proposed project is to identify endothelial receptors for carbamylated LDL and to systemically examine the impact of carbamylated LDL on the expression of inflammatory genes in human derived vascular endothelial cells.",
                "en": "In renal disease, elevated levels of urea lead to an increased concentration of cyanate that reacts irreversible with amino groups of proteins through carbamylation reactions. High concentrations of carbamylated low-density-lipoproteins (cLDL) have recently been reported to accumulate in plasma of pateints with chronic renal failure, indicating that cLDL is by far the most abundant modified LDL found in human plasa. Of importance, carbamylated proteins may also be formed directly at sites of inflammation - even in the absence of renal disease- via the phagocyte derived inflammatory mediator myeloperoxidase (MPO). Active MPO is present in human atherosclerotic lesion material and has been shown to bind to low- and high-density lipoproteins. Thus, it can be assumed that MPO derived cyanate contributes to lipoprotein carbamylation at sites of inflammation. Recent clinical studies demonstrated that carbamylated proteins predict increased risk of coronary artery disease, future myocardial infarction, stroke and death.\r\n\r\nNo endothelial receptors of binding proteins that might trigger the potent pro-atherosclerotic effects of carbamylated LDL have yet been identified. Therefore, the aim of the proposed project is to identify endothelial receptors for carbamylated LDL and to systemically examine the impact of carbamylated LDL on the expression of inflammatory genes in human derived vascular endothelial cells."
            },
            "begin_planned": "2008-10-01T02:00:00+02:00",
            "begin_effective": "2008-10-01T02:00:00+02:00",
            "end_planned": "2011-09-30T02:00:00+02:00",
            "end_effective": "2013-09-30T02:00:00+02:00",
            "assignment": "2008-07-14T14:41:55+02:00",
            "program": 72,
            "subprogram": null,
            "organization": 14022,
            "category": 10,
            "type": 10,
            "partner_function": 4,
            "manager": 53252,
            "contact": 53252,
            "status": 2,
            "research": 1,
            "grant": 10,
            "event": null,
            "study": null,
            "language": null,
            "funders": [
                9
            ],
            "funder_projectcode": "P21004",
            "ethics_committee": null,
            "edudract_number": null,
            "persons": [
                "1577-53252-10"
            ]
        },
        {
            "id": 1543,
            "title": {
                "de": "Expression und Lokalisierung der Endothel Lipase in stabilen und unstabilen atherosklerotischen Plaques",
                "en": "Expression and localization of endothelial lipase in stable and unstable atherosclerotic plaques"
            },
            "short": "EXPRESS_LOKALIS_ENDOTHEL_LIPASE",
            "url": null,
            "abstract": {
                "de": "Atherosklerose im Bereich der Karotiden ist Hauptverursacher des Schlaganfalles, einer der häufigsten Invaliditäts- und Todesursachen in den westlichen Industrieländern. Das Auftreten von neurologischen Symptomen bei betroffenen Patienten geht mit der Destabilisierung der atherosklerotischen Plaques einher. Da die Endothel Lipase in den Plaque-assoziierten Zellen exprimiert wird, wollen wir im Rahmen des beantragten Projektes untersuchen ob sich die Expressionsrate und die zellspezifische Lokalisierung der Endothel Lipase zwischen stabilen und unstabilen atherosklerotischen Plaques von Patienten nach operativer Endarterektomie unterscheidet. Die Ergebnisse dieser Studie versprechen neue Erkenntnisse über die Rolle von Endothel Lipase in der Entwicklung und Destabilisierung von karotidalen atherosklerotischen Plaques und stellen die Basis für die Entwicklung neuer Medikamente zur Prävention von Plaque-Destabilisierung dar.",
                "en": "Atherosklerose im Bereich der Karotiden ist Hauptverursacher des Schlaganfalles, einer der häufigsten Invaliditäts- und Todesursachen in den westlichen Industrieländern. Das Auftreten von neurologischen Symptomen bei betroffenen Patienten geht mit der Destabilisierung der atherosklerotischen Plaques einher. Da die Endothel Lipase in den Plaque-assoziierten Zellen exprimiert wird, wollen wir im Rahmen des beantragten Projektes untersuchen ob sich die Expressionsrate und die zellspezifische Lokalisierung der Endothel Lipase zwischen stabilen und unstabilen atherosklerotischen Plaques von Patienten nach operativer Endarterektomie unterscheidet. Die Ergebnisse dieser Studie versprechen neue Erkenntnisse über die Rolle von Endothel Lipase in der Entwicklung und Destabilisierung von karotidalen atherosklerotischen Plaques und stellen die Basis für die Entwicklung neuer Medikamente zur Prävention von Plaque-Destabilisierung dar."
            },
            "begin_planned": "2008-10-01T02:00:00+02:00",
            "begin_effective": "2008-10-01T02:00:00+02:00",
            "end_planned": "2011-09-30T02:00:00+02:00",
            "end_effective": "2011-09-30T02:00:00+02:00",
            "assignment": "2008-05-29T11:09:47+02:00",
            "program": 79,
            "subprogram": null,
            "organization": 14013,
            "category": 10,
            "type": 10,
            "partner_function": 4,
            "manager": 51988,
            "contact": 51988,
            "status": 2,
            "research": 1,
            "grant": 10,
            "event": null,
            "study": null,
            "language": null,
            "funders": [
                12
            ],
            "funder_projectcode": null,
            "ethics_committee": null,
            "edudract_number": null,
            "persons": [
                "1543-51988-10"
            ]
        },
        {
            "id": 1626,
            "title": {
                "de": "SPIDIA - Standardisation and improvement of pre-analytical procedures for in vitro diagnostics",
                "en": "SPIDIA - Standardisation and improvement of pre-analytical procedures for in vitro diagnostics"
            },
            "short": "SPIDIA",
            "url": null,
            "abstract": {
                "de": "In vitro diagnostics have allowed a great deal of progress in medicine but are limited by two factors: *the lack of guidelines in collection, handling, stabilisation and storage of biosamples which limits the reproducibility of subsequent diagnoses, and *its scale is restraines to the cellular level. To address this first point, this IP, SPIDIA, built of clinicians, academics, tool developers and assay developers, aims to develop quality guidelines for molecular in vitro diagnostics and to standardize the pre-analytical workflow in related procedures. Regarding the second point, SPIDIA aims to develop modern pre-analytical tools for diagnostic improving the stabilisation, handling and study of free biomolecules within blood, plasma, serum, tissues and tumours. Recent discoveries have revealed that RNA, DNA or proteins, released from pathological sites, like tumour cells or Alzheimer's disease brain lesions, into the blood or as a secondary blood based response to the disease can serve as biomarkers for early and reliable molecular diagnosis of such debilitating diseases. Further discoveries have shown that the cellular profiles of these molecules and structures in clinical samples can change during transport and storage thus making clinical assay results and pharmaceutical research unreliable or even impossible. It will therefore be a decisive prerequisite for future and current diagnostic assays to develop standards and new technologies, tools and devices that eliminate the human error in the pre-analytical steps of in vitro diagnostics. At this crucial moment in the development of molecular diagnostics, SPIDIA proposes an IP that reunites 7 private research companies (including 4 SMEs) and 8 public research organisms, including universities, hospitals and biobanks and an official European Standards Organisation. This strong consortium is balanced and empowered to maximise the impacts of in vitro diagnostics on human health.",
                "en": "In vitro diagnostics have allowed a great deal of progress in medicine but are limited by two factors: *the lack of guidelines in collection, handling, stabilisation and storage of biosamples which limits the reproducibility of subsequent diagnoses, and *its scale is restraines to the cellular level. To address this first point, this IP, SPIDIA, built of clinicians, academics, tool developers and assay developers, aims to develop quality guidelines for molecular in vitro diagnostics and to standardize the pre-analytical workflow in related procedures. Regarding the second point, SPIDIA aims to develop modern pre-analytical tools for diagnostic improving the stabilisation, handling and study of free biomolecules within blood, plasma, serum, tissues and tumours. Recent discoveries have revealed that RNA, DNA or proteins, released from pathological sites, like tumour cells or Alzheimer's disease brain lesions, into the blood or as a secondary blood based response to the disease can serve as biomarkers for early and reliable molecular diagnosis of such debilitating diseases. Further discoveries have shown that the cellular profiles of these molecules and structures in clinical samples can change during transport and storage thus making clinical assay results and pharmaceutical research unreliable or even impossible. It will therefore be a decisive prerequisite for future and current diagnostic assays to develop standards and new technologies, tools and devices that eliminate the human error in the pre-analytical steps of in vitro diagnostics. At this crucial moment in the development of molecular diagnostics, SPIDIA proposes an IP that reunites 7 private research companies (including 4 SMEs) and 8 public research organisms, including universities, hospitals and biobanks and an official European Standards Organisation. This strong consortium is balanced and empowered to maximise the impacts of in vitro diagnostics on human health."
            },
            "begin_planned": "2008-06-01T02:00:00+02:00",
            "begin_effective": "2008-10-01T02:00:00+02:00",
            "end_planned": "2012-05-31T02:00:00+02:00",
            "end_effective": "2013-03-31T01:00:00+01:00",
            "assignment": "2008-10-01T13:12:38+02:00",
            "program": 24,
            "subprogram": "HEALTH-2007-1.2-5",
            "organization": 14020,
            "category": 10,
            "type": 10,
            "partner_function": 2,
            "manager": 51663,
            "contact": 51663,
            "status": 2,
            "research": 1,
            "grant": 10,
            "event": null,
            "study": null,
            "language": null,
            "funders": [
                10
            ],
            "funder_projectcode": null,
            "ethics_committee": null,
            "edudract_number": null,
            "persons": [
                "1626-54279-12",
                "1626-51663-10"
            ]
        },
        {
            "id": 1936,
            "title": {
                "de": "CII-AT-0042-04-0809 - Medical Imaging & Medical Information Processing",
                "en": "CII-AT-0042-04-0809 - Medical Imaging & Medical Information Processing"
            },
            "short": "CEEPUS Medical Imaging",
            "url": null,
            "abstract": {
                "de": null,
                "en": null
            },
            "begin_planned": null,
            "begin_effective": "2008-10-01T02:00:00+02:00",
            "end_planned": null,
            "end_effective": "2009-09-30T02:00:00+02:00",
            "assignment": null,
            "program": null,
            "subprogram": null,
            "organization": 14106,
            "category": 10,
            "type": 10,
            "partner_function": 2,
            "manager": 51913,
            "contact": null,
            "status": 2,
            "research": 2,
            "grant": 10,
            "event": null,
            "study": null,
            "language": null,
            "funders": [],
            "funder_projectcode": null,
            "ethics_committee": null,
            "edudract_number": null,
            "persons": [
                "1936-83445-12",
                "1936-51824-12",
                "1936-51709-12",
                "1936-51913-10"
            ]
        },
        {
            "id": 1580,
            "title": {
                "de": "Albumin an acute-on-chronic liver failure: more than just volume? A randomized, controlled study",
                "en": "Albumin an acute-on-chronic liver failure: more than just volume? A randomized, controlled study"
            },
            "short": "LIVER_FAILURE",
            "url": null,
            "abstract": {
                "de": "Acute-on-chronic liver failure (ACLF) often results in multiple organ dysfunction and mortality rates are in the order of 50-90%.\r\nAlbumin is the major plasma protein and is produced in the liver. Albumin undertakes a variety of functions including: fatty acid transport; metal chelation; drug-binding; and anti-oxidant activity. In liver disease its concentration is diminished but the mechanism of this reduction is uncertain. Currently, albumin infusion in patients with cirrhosis is used primarily as a volume expander. However, recent studies showing reduction in severity of hepatic encephalopathy and improved survival of cirrhotic patients with spontaneous bacterial peritonitis and hepatorenal syndrome treated with albumin infusion is compelling.\r\nOne of the substances that bind to albumin is endotoxin. Endotoxin is a lipopolysaccharid derived from the wall of gram-negative bacteria that causes immediate and strong immune response.\r\n\r\nWe hypothesize that infusion of albumin can improve endotoxin binding capacity and thereby prevent inappropriate neutrophil activation and neutrophil dysfunction in patients with spontaneous bacterial peritonitits. Therefore we aim to investigate neutrophil function (oxidative burst and phagocytosis) and endotoxin binding capacity as well as albumin function in patients with spontaneous bacterial peritonitis before, during and after high-dose albumin infusions as compared to standard therapy. We will also record the occurence of organ failure as a clinical endpoint.",
                "en": "Acute-on-chronic liver failure (ACLF) often results in multiple organ dysfunction and mortality rates are in the order of 50-90%.\r\nAlbumin is the major plasma protein and is produced in the liver. Albumin undertakes a variety of functions including: fatty acid transport; metal chelation; drug-binding; and anti-oxidant activity. In liver disease its concentration is diminished but the mechanism of this reduction is uncertain. Currently, albumin infusion in patients with cirrhosis is used primarily as a volume expander. However, recent studies showing reduction in severity of hepatic encephalopathy and improved survival of cirrhotic patients with spontaneous bacterial peritonitis and hepatorenal syndrome treated with albumin infusion is compelling.\r\nOne of the substances that bind to albumin is endotoxin. Endotoxin is a lipopolysaccharid derived from the wall of gram-negative bacteria that causes immediate and strong immune response.\r\n\r\nWe hypothesize that infusion of albumin can improve endotoxin binding capacity and thereby prevent inappropriate neutrophil activation and neutrophil dysfunction in patients with spontaneous bacterial peritonitits. Therefore we aim to investigate neutrophil function (oxidative burst and phagocytosis) and endotoxin binding capacity as well as albumin function in patients with spontaneous bacterial peritonitis before, during and after high-dose albumin infusions as compared to standard therapy. We will also record the occurence of organ failure as a clinical endpoint."
            },
            "begin_planned": "2008-04-01T02:00:00+02:00",
            "begin_effective": "2008-10-01T02:00:00+02:00",
            "end_planned": "2010-03-31T02:00:00+02:00",
            "end_effective": "2011-09-30T02:00:00+02:00",
            "assignment": "2008-07-16T16:58:47+02:00",
            "program": 79,
            "subprogram": null,
            "organization": 14081,
            "category": 10,
            "type": 10,
            "partner_function": 4,
            "manager": 50989,
            "contact": 50989,
            "status": 2,
            "research": 2,
            "grant": 10,
            "event": null,
            "study": null,
            "language": null,
            "funders": [
                12
            ],
            "funder_projectcode": null,
            "ethics_committee": null,
            "edudract_number": null,
            "persons": [
                "1580-50989-10"
            ]
        },
        {
            "id": 1613,
            "title": {
                "de": "Glukose Monitoring bei der Hemodialyse",
                "en": "Glucose monitoring in hemodialysis"
            },
            "short": "GLUCOSEMONITORING_BRIDGE08",
            "url": null,
            "abstract": {
                "de": "Ziel des Projekts ist die Entwicklung eines Systems zur automatischen und kontinuierlichen Messung der Glukose bei der Hämodialyse und bei verwandten extrakorporalen Blutbehandlungsverfahren, sowie zur indirekten Bestimmung der Glukosekonzentration im Blut und davon abgeleiteter Größen.",
                "en": "To develop a system for automatic and continuous glucose measurements during hemodialysis and other related extracorporeal blood treatments for indirect estimation of arterial blood glucose and related entities."
            },
            "begin_planned": "2008-10-01T02:00:00+02:00",
            "begin_effective": "2008-10-01T02:00:00+02:00",
            "end_planned": "2010-11-30T01:00:00+01:00",
            "end_effective": "2011-03-31T02:00:00+02:00",
            "assignment": "2008-09-02T18:21:16+02:00",
            "program": 60,
            "subprogram": null,
            "organization": 14010,
            "category": 10,
            "type": 10,
            "partner_function": 4,
            "manager": 51834,
            "contact": 51834,
            "status": 2,
            "research": 3,
            "grant": 10,
            "event": null,
            "study": null,
            "language": null,
            "funders": [
                416
            ],
            "funder_projectcode": "818127",
            "ethics_committee": null,
            "edudract_number": null,
            "persons": [
                "1613-50404-12",
                "1613-51834-10"
            ]
        },
        {
            "id": 2161,
            "title": {
                "de": "BM.W_Fa-Zusatzfinanzierung 7. RP zu EU Projekt \"HEALTH-F5-2008-22916\" (SPIDIA)",
                "en": "BM.W_Fa-funding to the 7th EU FP \"HEALTH-F5-2008-22916\" (SPIDIA)"
            },
            "short": "BM.W_Fa Zusatzfinanzierung SPIDIA",
            "url": null,
            "abstract": {
                "de": null,
                "en": null
            },
            "begin_planned": "2008-10-01T02:00:00+02:00",
            "begin_effective": "2008-10-01T02:00:00+02:00",
            "end_planned": "2012-09-30T02:00:00+02:00",
            "end_effective": "2012-09-30T02:00:00+02:00",
            "assignment": "2010-03-15T13:01:21+01:00",
            "program": 90,
            "subprogram": null,
            "organization": 14020,
            "category": 10,
            "type": 10,
            "partner_function": 4,
            "manager": 51663,
            "contact": 51663,
            "status": 2,
            "research": 1,
            "grant": 10,
            "event": null,
            "study": null,
            "language": null,
            "funders": [
                25
            ],
            "funder_projectcode": null,
            "ethics_committee": null,
            "edudract_number": null,
            "persons": [
                "2161-51663-10"
            ]
        },
        {
            "id": 1671,
            "title": {
                "de": "Nachweis antibiotikarestistenter Escherichia coli-Stämme aus Klärschlamm unter Berücksichtigung der verschiedenen Klärschlammbehandlungsverfahren",
                "en": "Nachweis antibiotikarestistenter Escherichia coli-Stämme aus Klärschlamm unter Berücksichtigung der verschiedenen Klärschlammbehandlungsverfahren"
            },
            "short": "Escherichia coli-Stämme aus Klärschlamm ",
            "url": null,
            "abstract": {
                "de": "Die Ausbreitung resistenter Bakterien und antibiotisch wirksamer Substanzen aus Klärschlamm in die Umwelt ist derzeit nur schwer abschätzbar.\r\nIn der vorliegenden Studie sollten antibiotikaresistente Bakterien im Zusammenhang mit unterschiedlichen Behandlungs- und Hygienisierungsverfahren von Klärschlamm untersucht werden. Dabei sollten jene unterschiedlichen Verfahren verglichen werden bei welchen einerseits bei Einhaltung der richtigen Prozessbedingungen eine Entseuchung des Klärschlammes sichergestellt wird und andererseits die konventionellen Schlammbehandlungsverfahren, z.B. die anaerobe mesophile Faulung und die aerobe Stabilisierung.",
                "en": "Die Ausbreitung resistenter Bakterien und antibiotisch wirksamer Substanzen aus Klärschlamm in die Umwelt ist derzeit nur schwer abschätzbar.\r\nIn der vorliegenden Studie sollten antibiotikaresistente Bakterien im Zusammenhang mit unterschiedlichen Behandlungs- und Hygienisierungsverfahren von Klärschlamm untersucht werden. Dabei sollten jene unterschiedlichen Verfahren verglichen werden bei welchen einerseits bei Einhaltung der richtigen Prozessbedingungen eine Entseuchung des Klärschlammes sichergestellt wird und andererseits die konventionellen Schlammbehandlungsverfahren, z.B. die anaerobe mesophile Faulung und die aerobe Stabilisierung."
            },
            "begin_planned": "2009-01-01T01:00:00+01:00",
            "begin_effective": "2009-01-01T01:00:00+01:00",
            "end_planned": "2009-12-31T01:00:00+01:00",
            "end_effective": "2010-01-31T01:00:00+01:00",
            "assignment": "2008-12-04T12:26:09+01:00",
            "program": null,
            "subprogram": "Fördergeber Land Steiermark Fachabteilung 19D",
            "organization": 14023,
            "category": 10,
            "type": 10,
            "partner_function": 4,
            "manager": 51674,
            "contact": 51674,
            "status": 2,
            "research": 2,
            "grant": 10,
            "event": null,
            "study": null,
            "language": null,
            "funders": [
                135
            ],
            "funder_projectcode": null,
            "ethics_committee": null,
            "edudract_number": null,
            "persons": [
                "1671-51674-10"
            ]
        },
        {
            "id": 1706,
            "title": {
                "de": "Modulation des sensorimotorischen Kortex mittels anhaltender mechanischer und peripherer magnetischer Stimulation - Effektivität und therapeutisches Potential",
                "en": "Modulation of sensorimotor cortex by sustained mechanical and peripheral magnetic stimulation - effectiveness and therapeutical potential"
            },
            "short": "SENSORIMOTOR CORTEX_OENB2008",
            "url": null,
            "abstract": {
                "de": "Im vorliegenden Projektvorschlag soll überprüft werden, ob sich mittels afferenter Stimulation im Bereich von Finger und Hand poststimulatorische adaptive Effekte im sensomotorischen Kortex anregen lassen. Da solcherart neuoplastische Effekte mit einer erhöhten kortikospinalen Erregbarkeit einhergehen, eignen sich hier nichtinvasive Methoden wie TMS und fMRI für den Nachweis. Im Rahmen dieses Projekts sollen zwei Arten der afferenten Stimulation zur Anwendung kommen, die periphere Magnetstimulation und die biomechanische Stimulation. Bezüglich der Stimulationsfrequenz gibt es Hinweise dass eine Frequenz um 25 Hz optimal sein könnte (kortikale Resonanz), daher sollen hier 10 und 25 Hz getestet werden. Ziel des Projekts ist es die Post-Stimulus-Effekte bezüglich ihrer Effektstärke und Anhaltedauer zu charakterisieren und hinblicklich ihrer zugrunde liegenden Mechanismen (unmasking, LTP) zu diskutieren. Ein weiters Ziel ist es die Ergebnisse für die Neurorehabilitation nutzbar zu machen.",
                "en": "The proposed research examines the hypothesis that sustained somatosensory stimulation induces post-stimulus adaptive changes in primary motor cortex of healthy subjects. As such changes are associated with increased corticospinal excitability and reorganization of cortical networks, non-invasive assessment tools like transcranial magnetic stimulation (TMS) and functional magnetic resonance imaging (fMRI) are suited to evaluate the stimulation effects. Two types of sensory stimulation will be tested and compared here, repetitive peripheral magnetic stimulation (RPMS) of hand muscles and whole-hand mechanical stimulation (MSTIM). The research strategy employs a series of experiments to quantify the adaptive changes following stimulation protocols with different parameters. Specifically, we are interested into stimuli to effectively modulate the motor cortex, and into the reliability of the two assessment tools to quantify the post-stimulus effects. These experimental series will provide a fundamental scientific basis for better understanding how sustained sensory stimulation modulates central motor controlling structures and will help to evaluate the potential clinical benefit from the proposed stimulation techiques."
            },
            "begin_planned": "2009-01-01T01:00:00+01:00",
            "begin_effective": "2009-01-01T01:00:00+01:00",
            "end_planned": "2010-12-31T01:00:00+01:00",
            "end_effective": "2011-06-30T02:00:00+02:00",
            "assignment": "2008-12-22T11:08:25+01:00",
            "program": 79,
            "subprogram": null,
            "organization": 14010,
            "category": 10,
            "type": 10,
            "partner_function": 4,
            "manager": 51814,
            "contact": 51814,
            "status": 2,
            "research": 1,
            "grant": 10,
            "event": null,
            "study": null,
            "language": null,
            "funders": [
                12
            ],
            "funder_projectcode": null,
            "ethics_committee": null,
            "edudract_number": null,
            "persons": [
                "1706-51814-10"
            ]
        },
        {
            "id": 1734,
            "title": {
                "de": "Verkalkung von Gefäßen und Knochen bei NierentransplantationspatientInnen [Regulierung der Kalzifizierung bei NierentransplantationspatientInnen]",
                "en": "Verkalkung von Gefäßen und Knochen bei NierentransplantationspatientInnen [Regulierung der Kalzifizierung bei NierentransplantationspatientInnen]"
            },
            "short": "Verkalkung bei Nierentransplantationen",
            "url": null,
            "abstract": {
                "de": "Kalzifizierung tritt physiologisch im Knochen und pathophysiologisch im Gefäßsystem auf. Kardiovaskuläre Erkrankungen sind eine Haupt-Todesursache von Nierenerkrankten und sind entscheidend für die Durchführbarkeit von Nierentransplantationen (RTX). Das derezeitige Wissen um die Regulation der Kalzifizierung in Knochen und Gefäßsystem bei RTX-Patienten ist fragmentarisch.\r\n\r\nDiese offene, kontrollierte, monozentrische Studie untersucht die Regulation der Kalzifizierung im Knochen- und Gefäßsystem bei PatientInnen mit RTX.\r\nUnsere Fragestellung zielt auf Unterschiede der Expressionslevels von Regulatoren der Kalzifizierung in beiden Gewebstypen und im Vergleich von athero- und mediasklerotischen Gefäßen.\r\nWir erwarten uns Einblick in Kalzifizierungsmechanismen und mögliche klinische Aspekte für Diagnose und Therapie bei diesen HochrisikopatientInnen.",
                "en": "Kalzifizierung tritt physiologisch im Knochen und pathophysiologisch im Gefäßsystem auf. Kardiovaskuläre Erkrankungen sind eine Haupt-Todesursache von Nierenerkrankten und sind entscheidend für die Durchführbarkeit von Nierentransplantationen (RTX). Das derezeitige Wissen um die Regulation der Kalzifizierung in Knochen und Gefäßsystem bei RTX-Patienten ist fragmentarisch.\r\n\r\nDiese offene, kontrollierte, monozentrische Studie untersucht die Regulation der Kalzifizierung im Knochen- und Gefäßsystem bei PatientInnen mit RTX.\r\nUnsere Fragestellung zielt auf Unterschiede der Expressionslevels von Regulatoren der Kalzifizierung in beiden Gewebstypen und im Vergleich von athero- und mediasklerotischen Gefäßen.\r\nWir erwarten uns Einblick in Kalzifizierungsmechanismen und mögliche klinische Aspekte für Diagnose und Therapie bei diesen HochrisikopatientInnen."
            },
            "begin_planned": "2009-01-01T01:00:00+01:00",
            "begin_effective": "2009-01-01T01:00:00+01:00",
            "end_planned": "2011-12-31T01:00:00+01:00",
            "end_effective": "2012-12-31T01:00:00+01:00",
            "assignment": "2009-01-21T15:49:20+01:00",
            "program": 79,
            "subprogram": null,
            "organization": 14073,
            "category": 10,
            "type": 10,
            "partner_function": 4,
            "manager": 51982,
            "contact": 51982,
            "status": 2,
            "research": 2,
            "grant": 10,
            "event": null,
            "study": null,
            "language": null,
            "funders": [
                12
            ],
            "funder_projectcode": null,
            "ethics_committee": null,
            "edudract_number": null,
            "persons": [
                "1734-51982-10",
                "1734-57544-12"
            ]
        },
        {
            "id": 1957,
            "title": {
                "de": "Genetics of the Dopaminergic System and Smoking Behavior",
                "en": "Genetics of the Dopaminergic System and Smoking Behavior"
            },
            "short": "Genetics of the Dopaminergic System",
            "url": null,
            "abstract": {
                "de": null,
                "en": null
            },
            "begin_planned": null,
            "begin_effective": "2009-01-01T01:00:00+01:00",
            "end_planned": null,
            "end_effective": "2010-12-30T01:00:00+01:00",
            "assignment": "2009-10-23T12:55:40+02:00",
            "program": null,
            "subprogram": null,
            "organization": 14028,
            "category": 10,
            "type": 10,
            "partner_function": 4,
            "manager": 50910,
            "contact": 50910,
            "status": 2,
            "research": 2,
            "grant": 10,
            "event": null,
            "study": null,
            "language": null,
            "funders": [
                135
            ],
            "funder_projectcode": null,
            "ethics_committee": null,
            "edudract_number": null,
            "persons": [
                "1957-50910-10"
            ]
        },
        {
            "id": 1725,
            "title": {
                "de": "Role of T regulatory cells in polymorphic light eruption",
                "en": "Role of T regulatory cells in polymorphic light eruption"
            },
            "short": "polymorphic light eruption",
            "url": null,
            "abstract": {
                "de": "Die polymorphe Lichtdermatose (PLD- \"Sonnenallergie\"), deren Prävalenz (mit bis zu 20%) vor allem bei jungen Frauen außerordentlich hoch ist, ist durch an sonnenexponierten Körperstellen auftretende, stark juckende Hautveränderungen gekennzeichnet. Die Ätiopathogenese der PLD ist unbekannt, eine Störung der UV-induzierten Immunsuppression mit Immunreaktionen gegen Photoneoantigene der Haut wird vermutet. Bei der Immunsuppression nach UV-EInwirkung kommt den regulatorischen T-Zellen (CD4+CD25+FoxP3+) (Tregs), einer Subpoulation der T-Helfer Zellen, eine bedeutende Rolle zu.\r\nIm vorliegenden Projekt soll die Hypothese geprüft werden, dass Tregs von PLD-Patienten pathogenetisch bedeutsam im Jahresverlauf abnormal fluktuierende Spiegel und Funktionen aufweisen, welche möglicherweise durch Photohardening (UV-Abhärtung) normalisierbar sind. Aus einem besseren Verständnis der Pathogenese der PLD könnten möglicherweise Ansätze für neue therapeutische Strategien resultieren.",
                "en": "Die polymorphe Lichtdermatose (PLD- \"Sonnenallergie\"), deren Prävalenz (mit bis zu 20%) vor allem bei jungen Frauen außerordentlich hoch ist, ist durch an sonnenexponierten Körperstellen auftretende, stark juckende Hautveränderungen gekennzeichnet. Die Ätiopathogenese der PLD ist unbekannt, eine Störung der UV-induzierten Immunsuppression mit Immunreaktionen gegen Photoneoantigene der Haut wird vermutet. Bei der Immunsuppression nach UV-EInwirkung kommt den regulatorischen T-Zellen (CD4+CD25+FoxP3+) (Tregs), einer Subpoulation der T-Helfer Zellen, eine bedeutende Rolle zu.\r\nIm vorliegenden Projekt soll die Hypothese geprüft werden, dass Tregs von PLD-Patienten pathogenetisch bedeutsam im Jahresverlauf abnormal fluktuierende Spiegel und Funktionen aufweisen, welche möglicherweise durch Photohardening (UV-Abhärtung) normalisierbar sind. Aus einem besseren Verständnis der Pathogenese der PLD könnten möglicherweise Ansätze für neue therapeutische Strategien resultieren."
            },
            "begin_planned": "2009-01-01T01:00:00+01:00",
            "begin_effective": "2009-01-01T01:00:00+01:00",
            "end_planned": "2010-12-31T01:00:00+01:00",
            "end_effective": "2011-11-30T01:00:00+01:00",
            "assignment": "2009-01-16T14:41:21+01:00",
            "program": 79,
            "subprogram": null,
            "organization": 14047,
            "category": 10,
            "type": 10,
            "partner_function": 4,
            "manager": 51618,
            "contact": 51618,
            "status": 2,
            "research": 2,
            "grant": 10,
            "event": null,
            "study": null,
            "language": null,
            "funders": [
                12
            ],
            "funder_projectcode": null,
            "ethics_committee": null,
            "edudract_number": null,
            "persons": [
                "1725-54011-12",
                "1725-51618-10"
            ]
        }
    ]
}